AUTHORS

Real Money authors - Stephen Guilfoyle

Stephen Guilfoyle

Stephen "Sarge" Guilfoyle is the founder and President of Sarge986 LLC, a family run trading operation. An NYSE floor trader for over 30 years, Guilfoyle has served as the Chief Market Economist for Stuart Frankel & Co., the U.S. Economist for Meridian Equity Partners, and as a Vice President in Block Trading and Investment Banking with Credit Suisse over the years. Guilfoyle earned his nickname serving as an actual sergeant in reserve components of the US Marine Corps, and US Army while simultaneously working on Wall Street.
Email Stephen Guilfoyle

Recent Articles By The Author

Should You Invest in Regeneron, Lilly, or Gilead?

Invest either because of their profitable portfolio, their impressive pipeline, or their technical set-up.

Pelosi's Hardball Gambit, Playing Small Ball, Promising Vaccine Outlook

Plus, there's talk of a possible combination of Advanced Micro Devices and Xilinx.

IBM Makes a Smart Move, But How Should You Play the Stock?

The gauntlet has been thrown. Let the games begin.

Pricing in the Election, Politics and Investment Success, S&P 500 Resistance

As an investor, you are mercenary in nature. Never forget that. Politics and investment success must be compartmentalized.

My Position in Southwest Airlines Is Speculative for Now

This stock in my opinion is going to move violently in the short term.

Stimulus Repercussions, Is the Equities Rally Dead? Antitrust Action, Apple 5G

One day after deciding that we still could not confirm the market's uptrend, we are forced to ask the opposite.

Nvidia Climbs the Mountain Yet Again

I own it. I will continue to hold it. I would not sell it. For the uninvested who are interested, I would think small ball.

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.

Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?

BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.

Markets in Limbo, Stimulus Needed, Virus in Charge, Presidential Politics

The short-term story for financial markets has been all about fiscal policy. This remains true.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight